Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
about
Targeting the latent reservoir to achieve functional HIV cureEpigenetic control of HIV-1 post integration latency: implications for therapyImpact of Chromatin on HIV ReplicationManipulation of the host protein acetylation network by human immunodeficiency virus type 1Bromodomain proteins in HIV infectionOngoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsControlling the HIV/AIDS epidemic: current status and global challengesHIV-associated neurocognitive disorder.Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapiesReactivation of latent HIV-1 by new semi-synthetic ingenol esters.Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study.Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future DirectionsThe Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy).Euphorbia Kansui Reactivates Latent HIV.Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individualsThe BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.TFH in HIV Latency and as Sources of Replication-Competent VirusHIV-1 transcription and latency: an update.Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsDesign and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir.HIV-1 Latency and Eradication: Past, Present and FutureJanus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.Combined approaches for HIV cure.Is cure of HIV infection in sight?Reactivation of latent HIV by histone deacetylase inhibitors.Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.The long-term safety of antiepileptic drugs.Reactivation of latent HIV: do all roads go through P-TEFb?T Cell Transcription Factors and Their Impact on HIV Expression.HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions.Multiple Origins of Virus Persistence during Natural Control of HIV Infection.HIV-1 Eradication: Early Trials (and Tribulations).Perspectives on Human Immunodeficiency Virus (HIV) Cure: HIV Persistence in Tissue.A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4+ T-cells.The Alphabet Soup of HIV Reservoir Markers.Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.
P2860
Q26745923-A46AFC33-B527-43AB-B122-A479DD8983B8Q26781191-F922AEE1-D350-40C0-9987-9AC8B9FD6830Q26782046-8BE1A0DE-09F3-4E8B-A797-55F19E461D93Q26795463-B167E5B4-FACA-4314-9BC6-AEBA7A78DED6Q26829860-BA3DF416-1B2B-42AE-ACA9-8EDD9D6187A3Q28079455-DACC94C1-D8DD-44DD-8B42-0803DD283662Q30420558-E1C7DC20-2083-4513-AD0F-E11699EB2978Q33939729-E0774A55-3C2D-4BC7-BFFD-E1316E4246B7Q35141776-A30AAC0E-DB4E-4BC3-8F84-A557D6A18E38Q35252396-96FCB199-0890-4660-AC78-54311B6775F4Q35835849-4342EEC0-44E1-4D25-8368-56B1DD32FA67Q36030989-F329E578-4C2A-4B65-8C82-8A0C47B5328AQ36080407-9F4D819A-50B9-4949-AF35-F7E8593517D8Q36224979-4E1CCF98-F009-4AF8-9737-9352326652B1Q36525896-2F3BD632-ED0F-4B46-8B1D-72B77239578EQ36596027-CED4AFB9-B2C4-493E-B08B-1DBCB872D029Q36668708-0FD9565B-DBB6-4DE7-9445-DA1F2E5099D8Q36790027-31DD4A0C-3251-4EB4-ABC6-EA82EF2E72E0Q36827343-88BBD260-9A30-4F23-8023-254EF379B560Q36976156-F5ABA576-20AA-4D45-AA6B-874E3A199A8EQ37273652-E10AC1E8-5E7E-4BBB-A65B-E8672175EB2BQ37273660-388494EA-4E5B-48CB-9C01-8380EBED46BBQ37505823-79E38B98-FC3E-4E53-9DB6-C1CFFB75F1FCQ37522861-D4B45309-8B4B-42CA-B68E-919C7AF19852Q37626634-062FE74B-F58C-40E8-A4D3-38E5BBB0C522Q37664312-903BF648-EF6E-4B7A-A00C-032A92FC5E88Q37690804-3F9570C9-7346-4AA1-9D33-FDF9C34B381CQ38091753-2439E150-E695-41FA-8357-B08C673A06E3Q38096822-8C26D704-52A1-4F9F-B9B3-1E044827C30FQ38106856-9A1BDC63-077F-4327-B338-7397346D76CCQ38177273-604DA234-EEB6-44D7-A0D4-9BEC25C9DDB4Q38179375-2961B00F-6F09-4332-8C67-EBE73BB1C077Q38204866-11CE13D3-39FA-4A4E-B241-2645927B7E36Q38246141-633ABE2E-A644-48C1-B44B-D1D93EDBDE9AQ38379102-A8263703-882A-4500-AF62-600F6380C7B3Q38675631-CE604224-7A3E-4B10-A08E-83F4CCAC44BAQ38682294-48B02A02-348C-431E-B931-20F3FD17C883Q38795594-8192D31C-0CCA-41E2-AC61-C47C3C6AF353Q39237000-B3654A8D-EAFE-4738-9CF3-C17F8B4239BBQ40069803-016D8362-7936-426A-8B14-3150676C5535
P2860
Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Valproic acid in association w ...... tre randomized clinical study.
@ast
Valproic acid in association w ...... tre randomized clinical study.
@en
Valproic acid in association w ...... tre randomized clinical study.
@nl
type
label
Valproic acid in association w ...... tre randomized clinical study.
@ast
Valproic acid in association w ...... tre randomized clinical study.
@en
Valproic acid in association w ...... tre randomized clinical study.
@nl
prefLabel
Valproic acid in association w ...... tre randomized clinical study.
@ast
Valproic acid in association w ...... tre randomized clinical study.
@en
Valproic acid in association w ...... tre randomized clinical study.
@nl
P2093
P2860
P1433
P1476
Valproic acid in association w ...... ntre randomized clinical study
@en
P2093
B Trottier
C L Tremblay
M R Boulassel
R P Sékaly
S Trottier
P2860
P304
P356
10.1111/J.1468-1293.2011.00975.X
P577
2012-01-26T00:00:00Z